Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study

Wietske Kievit*, Noortje van Herwaarden, Frank H. J. van den Hoogen, Ronald F. van Vollenhoven, Johannes W. J. Bijlsma, Bart J. F. van den Bemt, Aatke van der Maas, Alfons A. den Broeder

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

29 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1939-1944
JournalAnnals of the Rheumatic Diseases
Issue number11
Publication statusPublished - Nov 2016

Cite this